PFO
EDIT icon

Pathstone Family Office’s Editas Medicine EDIT Stock Holding History

Pathstone Family Office’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,933
Closed -$223K – 876
2021
Q2 		$223K Buy
+3,933
New +$145K 0.01% 740

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pathstone Family Office's EDIT Position: Q3 2021 in Review

Pathstone Family Office sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 3,933 shares — an estimated $223K sold.

Pathstone Family Office first reported a position in EDIT in Q2 2021 and held it in 1 quarter. The position peaked at $223K in Q2 2021. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

  • Pathstone Family Office reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
  • Pathstone Family Office sold 3,933 Editas Medicine shares in Q3 2021, an estimated $223K.
  • Pathstone Family Office first reported a position in Editas Medicine in Q2 2021 and held it in 1 quarter.
  • Pathstone Family Office's Editas Medicine position peaked at $223K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Pathstone Family Office's 13F filing for Q3 2021, filed 16 Nov 2021.